Careers  |  Sign In  |  Register  |   Twitter

Semen Test May Improve Accuracy in Diagnosing Prostate Cancer

As the second most common cancer in American men, prostate cancer is responsible for around 30,000 annual deaths. An article published by Bloomberg News addresses the shortcomings of the current methods of diagnosis, which include a PSA test that often over-diagnoses or over-treats with little efficacy. In analyzing seminal fluid samples from a group of men, researchers found microRNAs, molecules known to be raised in prostate cancer, deemed to be “surprisingly accurate in detecting the cancer and its severity.”

Read the article published in Bloomberg News.